Methodology
How we score GLP-1 telehealth programs (v4.1)
Released: · Last reviewed: · By Dr. Parmis
We score programs on the v4.1 rubric: 100 points across 7 weighted categories and 17 sub-checks, using facts read on each program's own pages, never marketing claims we cannot trace. Scores were recomputed for every readable program on November 20, 2026.
Rubric weights (100 points total)
Every program is scored against the same seven categories. We do not adjust weights per program, and compensation never changes a score.
| Category | Points | What we look for |
|---|---|---|
| Pricing transparency | 20 | Drug price printed and read on the program's own page; medication and care in one price or every required fee printed; price at every dose knowable; plan term and billing stated consistently (sub-checks PT1-PT4). |
| Total annual cost | 20 | The cheapest 12-month cost a new patient can buy at the standing price, including any required membership, against the lowest computable cost for the same drug among scored programs; "from" prices count at half weight (AN). |
| Clinical oversight | 15 | Prescribing medical group named, prescriber licensure or certification stated, clinical lead named with credential (CO1-CO3). |
| Pharmacy transparency | 15 | Dispensing pharmacy named, or for brand-only programs prescriptions sent to the pharmacy you choose; pharmacy class or licensure stated (PH1-PH2). |
| Support | 10 | Two or more contact channels, how to cancel, and the conditions under which money is refunded (SU1-SU3). |
| Regulatory disclosure | 10 | Compounded products described as not FDA-approved, and no open FDA warning letter in FDA's index (RD1-RD2). |
| Accessibility | 10 | Where the program operates, payment options beyond a card, and whether you can start month to month (AC1-AC3). |
The 17 sub-checks
Each category is split into sub-checks that a reader can repeat on the program's own pages. Points are given for what the pages say on the read date; a statement we could not find scores lower than one we could, and a program whose pages we could not read is not scored at all.
| ID | Category | Points | What earns the points |
|---|---|---|---|
| PT1 | Pricing transparency | 5 | Drug price printed on the program's own page, read in the November 20, 2026 re-read |
| PT2 | Pricing transparency | 5 | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) |
| PT3 | Pricing transparency | 5 | Price at every dose knowable: same price at every dose, or a full dose ladder |
| PT4 | Pricing transparency | 5 | Plan term and billing interval stated (2 if the program's own pages disagree) |
| CO1 | Clinical oversight | 9 | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) |
| CO2 | Clinical oversight | 3 | Prescribers' licensure or certification stated |
| CO3 | Clinical oversight | 3 | Clinical lead (medical director or chief medical officer) named with credential |
| PH1 | Pharmacy transparency | 10 | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) |
| PH2 | Pharmacy transparency | 5 | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) |
| SU1 | Support | 4 | Two or more contact channels published (4), one (2) |
| SU2 | Support | 3 | How to cancel is stated |
| SU3 | Support | 3 | Refund terms are stated (any stated condition under which money is refunded or credited) |
| RD1 | Regulatory disclosure | 5 | Compounded products described as not FDA-approved; brand-only programs (5) |
| RD2 | Regulatory disclosure | 5 | No open FDA warning letter in FDA's index (read November 20, 2026) |
| AC1 | Accessibility | 4 | Where it operates stated clearly (4); vague or conflicting statements (2) |
| AC2 | Accessibility | 3 | Payment beyond a card stated (HSA/FSA or pay-later) |
| AC3 | Accessibility | 3 | Can start month to month without a multi-month commitment |
| AN | Total annual cost | 20 | 20 × (lowest 12-month cost for the same drug among scored programs ÷ this program's 12-month cost), using its better-scoring drug; a "from" or starting-dose price counts at half weight; no drug price, or medication not included, scores 0 |
How the ranking is ordered
- The order is the computed total. On November 20, 2026, NexLife scores 87 of 100 and ranks first of 15 scored programs; Eden is second at 85.2. The margin rests on judgment calls that are written down: counting Eden's Chief Medical Innovation Officer as a clinical lead (sub-check CO3) would add 3 points and put Eden first.
- FDA warning letters count the same for everyone. An open letter in FDA's warning-letter index (read November 20, 2026) removes the 5 points of RD2. Four scored programs lose them: NexLife (730096), Eden (728279), IVIM Health (721816) and Zappy Health (717991). MEDVi and Hims & Hers also have open letters but are not scored.
- Unreadable programs are not scored. 5 programs whose pages blocked the November 20 re-read, or showed prices only in a browser, are listed as not scored, with the reason, rather than given zeros.
- To test this ranking, or any other, use our guide how to check a GLP-1 provider ranking.
- A rank describes disclosure and price clarity on the read date. The price page shows each program's dated price beside NexLife's, including programs that charge the same or less on a given plan.
Scores, November 20, 2026
| Rank | Program | Pricing transparency (20) | Total annual cost (20) | Clinical oversight (15) | Pharmacy transparency (15) | Support (10) | Regulatory disclosure (10) | Accessibility (10) | Total (100) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NexLife | 14.0 | 20.0 | 15.0 | 15.0 | 10.0 | 5.0 | 8.0 | 87.0 |
| 2 | Eden | 20.0 | 19.2 | 6.0 | 15.0 | 10.0 | 5.0 | 10.0 | 85.2 |
| 3 | Enhance.MD | 20.0 | 7.6 | 12.0 | 15.0 | 10.0 | 10.0 | 7.0 | 81.6 |
| 4 | Found | 20.0 | 11.8 | 12.0 | 9.0 | 10.0 | 10.0 | 8.0 | 80.8 |
| 5 | Mochi Health | 15.0 | 8.7 | 12.0 | 7.0 | 10.0 | 10.0 | 10.0 | 72.7 |
| 6 | Zappy Health | 20.0 | 9.1 | 5.0 | 9.0 | 10.0 | 5.0 | 10.0 | 68.1 |
| 7 | Henry Meds | 20.0 | 9.6 | 5.0 | 9.0 | 10.0 | 10.0 | 3.0 | 66.6 |
| 8 | Noom Med | 12.0 | 7.4 | 5.0 | 7.0 | 10.0 | 10.0 | 5.0 | 56.4 |
| 9 | Form Health | 0.0 | 0.0 | 12.0 | 15.0 | 10.0 | 10.0 | 8.0 | 55.0 |
| 10 | IVIM Health | 10.0 | 6.8 | 9.0 | 10.0 | 8.0 | 5.0 | 5.0 | 53.8 |
| 11 | WeightWatchers Clinic | 5.0 | 0.0 | 12.0 | 15.0 | 10.0 | 10.0 | 0.0 | 52.0 |
| 12 | Shed | 5.0 | 4.8 | 5.0 | 7.0 | 10.0 | 10.0 | 10.0 | 51.8 |
| 13 | Oak Longevity | 5.0 | 0.0 | 5.0 | 7.0 | 10.0 | 10.0 | 10.0 | 47.0 |
| 14 | PlushCare | 0.0 | 0.0 | 5.0 | 15.0 | 10.0 | 10.0 | 6.0 | 46.0 |
| 15 | Calibrate | 5.0 | 0.0 | 12.0 | 0.0 | 8.0 | 10.0 | 7.0 | 42.0 |
Total annual cost inputs
Each program's 12-month cost is the cheapest plan a new patient could buy for a year at the standing price shown on November 20, 2026, including any required membership: 12 monthly shipments, or 13 four-week cycles for programs that bill by 28-day, 4-week or 12-week cycles. Benchmarks: compounded tirzepatide $1,380, compounded semaglutide $1,140.
| Program | Tirzepatide, 12 months (USD) | Semaglutide, 12 months (USD) | Points (20) |
|---|---|---|---|
| NexLife | $1,380 12-month plan: 12 × $115 | $1,140 12-month plan: 12 × $95 | 20.0 |
| Eden | $1,548 monthly: 12 × $129 | $1,188 monthly: 12 × $99 | 19.2 |
| Enhance.MD | $3,640 48-week billing: 13 × $280 per 4 weeks | no drug-specific price | 7.6 |
| Found | $2,587 12-month term: 13 × $199 per 28-day cycle | $1,937 12-month term: 13 × $149 per 28-day cycle | 11.8 |
| Mochi Health | $1,668 (minimum) 12-month membership: 12 × ($49 + $90 starting dose) | $1,308 (minimum) 12-month membership: 12 × ($49 + $60 starting dose) | 8.7 |
| Zappy Health | $3,588 two 6-month plans: 2 × $1,794 | $2,508 two 6-month plans: 2 × $1,254 | 9.1 |
| Henry Meds | no price printed | $2,364 12 months paid in full | 9.6 |
| Noom Med | $3,737 $149 first 4 weeks + 4 × $897 per 12 weeks | $3,117 $129 first 4 weeks + 4 × $747 per 12 weeks ($249/mo) | 7.4 |
| IVIM Health | $2,304 (minimum) 12 × ($117 'starting at' + $75 program fee) | $1,680 (minimum) 12 × ($65 'starting at' + $75 program fee) | 6.8 |
| Shed | $2,868 (minimum) 12 × $239 'starting as low as' | no drug-specific price | 4.8 |
No annual cost could be computed for Form Health, WeightWatchers Clinic, Oak Longevity, PlushCare, Calibrate: their pages print no drug price, or say medication is not included.
What changed on November 20, 2026
From November 10 to November 20, 2026 this page published a fixed score of 94 for NexLife before any other program had been scored. On November 20 we scored every readable program on the same 17 sub-checks. NexLife computes to 87.0: it loses 5 points for its open FDA warning letter, 3 because its own price figures disagree (its sublingual semaglutide page), 3 because its pages disagree on whether multi-month plans are billed monthly or upfront, and 2 because they disagree on how many states it serves. It still ranks first, 1.8 points ahead of Eden. The correction is logged on the corrections page.
What counts as evidence
Every price and factual claim carries an evidence label: provider-reported (read on the program's own page, with the date), third-party-reported (from a source the program does not control), primary-source-linked (a government, registry or peer-reviewed source) or unverified (no source on file). See theevidence policy and the pricing method.
What this methodology does not do
The rubric scores disclosed facts. It is not medical advice, does not assess clinical outcomes for any individual, and does not replace checking licensure, price and pharmacy directly with a program before you enroll. See our medical disclaimer.
Frequently asked questions
How does GLP Ranked score GLP-1 telehealth programs?
GLP Ranked scores GLP-1 telehealth programs on its v4.1 rubric of 100 points, pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10, split into 17 published sub-checks applied to every program whose own pages we could read on November 20, 2026. Fifteen programs were scored; NexLife leads at 87. An open FDA warning letter costs any program 5 points. Each review page shows the program's inputs and arithmetic, so you can redo the score yourself.
Cite this page
GLP Ranked. "How we score GLP-1 telehealth programs (v4.1)." https://glpranked.com/methodology/
GLP Ranked. "How we score GLP-1 telehealth programs (v4.1)." https://glpranked.com/methodology/